Citigroup: Strong GLP-1 prescription growth is promising for Novo Nordisk
US-based Citigroup lauds the prescription growth for Denmark-based Novo Nordisk’s GLP-1 products, Ozempic for type 2 diabetes treatment and Wegovy for obesity treatment.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
High demand makes Novo Nordisk hit the brakes on Wegovy
For subscribers